Catherine Martel, Sylvie Cointe, Pascal Maurice, Saïd Matar, Marta Ghitescu, Pierre Théroux, Arnaud Bonnefoy
Index: PLoS ONE 6 , e18812, (2011)
Full Text: HTML
The activation of complement during platelet activation is incompletely understood.We sought to explore the formation of C5b-9 and anaphylatoxins binding to collagen-activated platelets.C5b-9, anaphylatoxins C3a, C4a and C5a, and anaphylatoxin receptors C3aR1 and C5aR were measured by flow cytometry and/or confocal microscopy. Platelet microparticles were quantified by flow cytometry, and their C5b-9 content was determined by western blot analyses. In all experiments, sodium citrate was used for blood anticoagulation.C5b-9 rapidly formed on the platelet surface following activation with collagen, TRAP, ADP or A23187, but was surprisingly restricted to a subset of platelets (1 to 15%) independently of P-selectin or phosphatidylserine exposure. Following collagen activation, C5b-9-positive platelets in thrombi were found associated with collagen fibres. C5b-9 formation was obliterated by Mg(2+)-EGTA and significantly reduced by the thrombin inhibitor hirudin (-37%, p<0.05), but was unaffected by chondroitinase, compstatin, SCH79797 (PAR-1 inhibitor), or in the PRP of a MBL-deficient donor. Compstatin and Mg(2+)-EGTA, but not hirudin, SCH79797 or chondroitinase, inhibited the formation of collagen-induced microparticles (-71% and -44%, respectively, p<0.04). These microparticles contained greater amounts of C5b-9 compared with the other agonists. Platelet activation by collagen or convulxin resulted in the strong binding of anaphylatoxins and the exposure of receptors C3aR1 and C5aR (CD88) on their surface.C5b-9 formation on collagen-activated platelets is i) partially controlled by thrombin, ii) restricted to a subset of platelets, and iii) can occur without P-selectin expression or phosphatidylserine exposure. Activated platelets bind anaphylatoxins on their surface and express C3a and C5a receptors, which may contribute to the localization of inflammatory processes during thrombosis.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Nafamostat mesylate
CAS:82956-11-4 |
C21H25N5O8S2 |
A novel protocol allowing oral delivery of a protein complem...
2014-08-01 [Clin. Exp. Immunol. 177(2) , 500-8, (2014)] |
Elevation of the terminal complement activation products C5a...
2014-11-15 [J. Neuroimmunol. 276(1-2) , 213-8, (2015)] |
TMPRSS2, a novel membrane-anchored mediator in cancer pain.
2015-05-01 [Pain 156 , 923-30, (2015)] |
Live cell evaluation of granzyme delivery and death receptor...
2015-08-20 [Blood 126 , e1-e10, (2015)] |
Coagulation induced by C3aR-dependent NETosis drives protumo...
2016-01-01 [Nat. Commun. 7 , 11037, (2016)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved